Confronto

Octreotide vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

83150-76-9

396091-73-9

Peso molecolare

1019.24 g/mol

1047.21 g/mol

Emivita

1.7 h

nessun dato

Sequenza

D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)

nessun dato

Meccanismo d'azione

Octreotide

Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Octreotide	Pasireotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Octreotide and Pasireotid?: Octreotide is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Octreotide or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Octreotide and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Octreotide and Pasireotid in Germany and the United States?: Germania: Octreotide — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Octreotide — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Octreotide

Pasireotid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Octreotide and Pasireotid?

Octreotide is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Octreotide or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Octreotide and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Octreotide and Pasireotid in Germany and the United States?

Germania: Octreotide — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Octreotide — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.